Search
CELL BANK Website

Back Back
Cell No. : Cell Name
RCB1032 : NOS-1  update : 2024/10/11
CommentOsteoid producing in vitro and in nude mice.
Comment from the depositor
Terms and conditionsThere is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC.
Remarks
Order Form Order Form(C-0005.pdf)   MTA(C-0007.pdf)   MTA(C-0007p.pdf)  
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
Basic information Depositor Motoyama, Teiichi
Originator Hotta, Tetsuo & Motoyama, Teiichi
Year of deposit 1994
Animal _human < Mammals
Genus Homo
Species sapiens
Race Japanese
Gender Male
Age at sampling 16 years
Tissue bone
Disease name osteosarcoma
Metastatic ability Yes
Metastatic tissue lung
Classification cancer
Year of origin 1989
Lifespan infinite
Morphology other
Cellosaurus(Expasy) CVCL_1610
deposit info
lot info
Medium Medium List
Culture type Adherent cells
Culture medium RPMI1640 + 10% FBS
Antibiotics Free
Passage method 0.25% Trypsin
Culture information Passage ratio 1 : 8 split
SC frequency Subculture : once/1-2 weeks, Medium Renewal : 2 times/week
Temperature 37 ℃
CO2 concentration 5 %
Freeze medium Medium + 10% DMSO
Freezing method Slow freezing
Mycoplasma/Acholeplasma (-)
Virus (HIV) (-)
Isozyme LD, NP
Chromosome mode 66-135(50) : 66(6),67(4),68(2),69(9),70(13),71(6)/
STR(human) OK
Images
deposit info
lot info
Reference information Reference 3
User's Publication 30


To topTop
Reference
16680  Kusabe Y, Kawashima H, Ogose A, Sasaki T, Ariizumi T, Hotta T, Endo N.  Effect of temozolomide on the viability of musculoskeletal sarcoma cells  Oncol Lett  2015  10(4):2511-2518  PubMed ID: 26622881   DOI: 10.3892/ol.2015.3506
1936  Motoyama T, Hotta T, Watanabe H, Kumanishi T, Ichikawa T, Sekiguchi M  Differetial production of interleukin 6 in human osteosarcoma cells and the possible effects on neoplastic bone metabolism  Virchows Arch B Cell Pathol  1993  63:277-281  PubMed ID: 8100098   DOI: 10.1007/bf02899273
1935  Hotta T, Motoyama T, Watanabe H  Three human osteosarcoma cell lines exhibiting different phenotypic expressions.  Acta Pathol Jpn  1992  42:595-603  PubMed ID: 1449054   DOI: 10.1111/j.1440-1827.1992.tb03110.x

To topTop
User's Publication
22529  Oyama T, Brashears CB, Rathore R, Benect-Hamilton H, Caldwell KE, Dirckx N, Hawkins WG, Van Tine BA.  PHGDH inhibition and FOXO3 modulation drives PUMA-dependent apoptosis in osteosarcoma.  Cell Death Dis  2025  16(1):89  PubMed ID: 39934141   DOI: 10.1038/s41419-025-07378-6
21832  Kojima Y, Fujieda S, Zhou L, Takikawa M, Kuramochi K, Furuya T, Mizumoto A, Kagaya N, Kawahara T, Shin-Ya K, Dan S, Tomida A, Ishikawa F, Sadaie M.  Cytochrome P450 2J2 is required for the natural compound austocystin D to elicit cancer cell toxicity.  Cancer Sci  2024    PubMed ID: 39009033   DOI: 10.1111/cas.16289
22145  Chow T, Humble W, Lucarelli E, Onofrillo C, Choong PF, Di Bella C, Duchi S.  Feasibility and barriers to rapid establishment of patient-derived primary osteosarcoma cell lines in clinical management.  iScience  2024  27(9):110251  PubMed ID: 39286504   DOI: 10.1016/j.isci.2024.110251
22469  Ueno T, Otani S, Date Y, Katsuma Y, Nagayoshi Y, Ito T, Ii H, Kageyama S, Nakata S, Ito K.  Myc upregulates Ggct, γ-glutamylcyclotransferase to promote development of p53-deficient osteosarcoma  Cancer Sci  2024  115(9):2961-2971  PubMed ID: 38924236   DOI: 10.1111/cas.16255
17357  Hayashi T, Yamamoto N, Kurosawa G, Tajima K, Kondo M, Hiramatsu N, Kato Y, Tanaka M, Yamaguchi H, Kurosawa Y, Yamada H, Fujita N.  A Novel High-Throughput Screening Method for a Human Multicentric Osteosarcoma-Specific Antibody and Biomarker Using a Phage Display-Derived Monoclonal Antibody  Cancers (Basel)  2022  14(23):5829  PubMed ID: 36497311   DOI: 10.3390/cancers14235829
13409  Hirozane T, Masuda M, Sugano T, Sekita T, Goto N, Aoyama T, Sakagami T, Uno Y, Moriyama H, Sawa M, Asano N, Nakamura M, Matsumoto M, Nakayama R, Kondo T, Kawai A, Kobayashi E, Yamada T.  Direct conversion of osteosarcoma to adipocytes by targeting TNIK.  JCI Insight  2021    PubMed ID: 33400690   DOI: 10.1172/jci.insight.137245
20022  Rathore R, Caldwell KE, Schutt C, Brashears CB, Prudner BC, Ehrhardt WR, Leung CH, Lin H, Daw NC, Beird HC, Giles A, Wang WL, Lazar AJ, Chrisinger JSA, Livingston JA, Van Tine BA.  Metabolic compensation activates pro-survival mTORC1 signaling upon 3-phosphoglycerate dehydrogenase inhibition in osteosarcoma.  Cell Rep  2021  34(4):108678  PubMed ID: 33503424   DOI: 10.1016/j.celrep.2020.108678
13253  Fujiwara S, Kawamoto T, Kawakami Y, Koterazawa Y, Hara H, Takemori T, Kitayama K, Yahiro S, Kakutani K, Matsumoto T, Matsushita T, Niikura T, Koyanagi-Aoi M, Aoi T, Kuroda R, Akisue T.  Acquisition of cancer stem cell properties in osteosarcoma cells by defined factors.  Stem Cell Res Ther  2020    PubMed ID: 33008481   DOI: 10.1186/s13287-020-01944-9
19258  Kobayashi E, Masuda M, Nakayama R, Ichikawa H, Satow R, Shitashige M, Honda K, Yamaguchi U, Shoji A, Tochigi N, Morioka H, Toyama Y, Hirohashi S, Kawai A, Yamada T.  Reduced argininosuccinate synthetase is a predictive biomarker for the development of pulmonary metastasis in patients with osteosarcoma  Mol Cancer Ther  2019  9(3):535-44  PubMed ID: 20159990   DOI: 10.1158/1535-7163.MCT-09-0774
7043  Ando T, Kudo Y, Iizuka S, Tsunematsu T, Umehara H, Shrestha M, Matsuo T, Kubo T, Shimose S, Arihiro K, Ogawa I, Ochi M, Takata T.  Ameloblastin induces tumor suppressive phenotype and enhances chemosensitivity to doxorubicin via Src-Stat3 inactivation in osteosarcoma.  Sci Rep  2017  7:40187  PubMed ID: 28054649   DOI: 10.1038/srep40187
10039  Takahashi K, Setoguchi T, Tsuru A, Saitoh Y, Nagano S, Ishidou Y, Maeda S, Furukawa T, Komiya S.  Inhibition of casein kinase 2 prevents growth of human osteosarcoma.  Oncol. Rep.  2017  37:1141-1147  PubMed ID: 27959425   DOI: 10.3892/or.2016.5310
7459  Tsuru A, Setoguchi T, Matsunoshita Y, Nagao-Kitamoto H, Nagano S, Yokouchi M, Maeda S, Ishidou Y, Yamamoto T, Komiya S.  Hairy/enhancer-of-split related with YRPW motif protein 1 promotes osteosarcoma metastasis via matrix metallopeptidase 9 expression.  Br. J. Cancer  2015  112:1232-40  PubMed ID: 25742474   DOI: 10.1038/bjc.2015.84
6426  Igawa K, Xie MF, Ohba H, Yamada S, Hayashi Y.  D-glucosamine conjugation accelerates the labeling efficiency of quantum dots in osteoblastic cells.  Biomed Res Int  2014  2014:821607  PubMed ID: 24818156   DOI: 10.1155/2014/821607
6427  Kobayashi E, Satow R, Ono M, Masuda M, Honda K, Sakuma T, Kawai A, Morioka H, Toyama Y, Yamada T.  MicroRNA expression and functional profiles of osteosarcoma.  Oncology  2014  86(2):94-103  PubMed ID: 24457375   DOI: 10.1159/000357408
6428  Arai K, Sakamoto R, Kubota D, Kondo T.  Proteomic approach toward molecular backgrounds of drug resistance of osteosarcoma cells in spheroid culture system.  Proteomics  2013  13(15):2351-60  PubMed ID: 23712969   DOI: 10.1002/pmic.201300053
6431  Shibuya H, Hamamura K, Hotta H, Matsumoto Y, Nishida Y, Hattori H, Furukawa K, Ueda M, Furukawa K.  Enhancement of malignant properties of human osteosarcoma cells with disialyl gangliosides GD2/GD3.  Cancer Sci  2012  103(9):1656-64  PubMed ID: 22632091   DOI: 10.1111/j.1349-7006.2012.02344.x
7968  Matsunoshita Y, Ijiri K, Ishidou Y, Nagano S, Yamamoto T, Nagao H, Komiya S, Setoguchi T.  Suppression of osteosarcoma cell invasion by chemotherapy is mediated by urokinase plasminogen activator activity via up-regulation of EGR1.  PLoS ONE  2011  6:e16234  PubMed ID: 21283769   DOI: 10.1371/journal.pone.0016234
8031  Iizuka S, Kudo Y, Yoshida M, Tsunematsu T, Yoshiko Y, Uchida T, Ogawa I, Miyauchi M, Takata T.  Ameloblastin regulates osteogenic differentiation by inhibiting Src kinase via cross talk between integrin beta1 and CD63.  Mol. Cell. Biol.  2011  31:783-92  PubMed ID: 21149578   DOI: 10.1128/MCB.00912-10
18257  Hirotsu M, Setoguchi T, Sasaki H, Matsunoshita Y, Gao H, Nagao H, Kunigou O, Komiya S.  Smoothened as a new therapeutic target for human osteosarcoma  Mol Cancer  2010  9:5  PubMed ID: 20067614   DOI: 10.1186/1476-4598-9-5
5180  Sasaki H, Setoguchi T, Matsunoshita Y, Gao H, Hirotsu M, Komiya S.  The knock-down of overexpressed EZH2 and BMI-1 does not prevent osteosarcoma growth.  Oncol Rep  2010  23(3):677-84  PubMed ID: 20127006   DOI: 10.3892/or_00000684
8566  Morioka K, Tanikawa C, Ochi K, Daigo Y, Katagiri T, Kawano H, Kawaguchi H, Myoui A, Yoshikawa H, Naka N, Araki N, Kudawara I, Ieguchi M, Nakamura K, Nakamura Y, Matsuda K.  Orphan receptor tyrosine kinase ROR2 as a potential therapeutic target for osteosarcoma.  Cancer Sci.  2009  100:1227-33  PubMed ID: 19486338   DOI: 10.1111/j.1349-7006.2009.01165.x
6435  Yamaguchi U, Honda K, Satow R, Kobayashi E, Nakayama R, Ichikawa H, Shoji A, Shitashige M, Masuda M, Kawai A, Chuman H, Iwamoto Y, Hirohashi S, Yamada T.  Functional genome screen for therapeutic targets of osteosarcoma.  Cancer Sci  2009  100(12):2268-74  PubMed ID: 19725836   DOI: 10.1111/j.1349-7006.2009.01310.x
6437  Maehara H, Kaname T, Yanagi K, Hanzawa H, Owan I, Kinjou T, Kadomatsu K, Ikematsu S, Iwamasa T, Kanaya F, Naritomi K.  Midkine as a novel target for antibody therapy in osteosarcoma.  Biochem Biophys Res Commun  2007  358(3):757-62  PubMed ID: 17506984   DOI: 10.1016/j.bbrc.2007.04.183
6438  Osaka E, Suzuki T, Osaka S, Yoshida Y, Sugita H, Asami S, Tabata K, Sugitani M, Nemoto N, Ryu J.  Survivin expression levels as independent predictors of survival for osteosarcoma patients.  J Orthop Res  2007  25(1):116-21  PubMed ID: 17034065   DOI: 10.1002/jor.20291
6439  Miyazawa K, Kakazu N, Ohyashiki K.  Clinical features of hypereosinophilic syndrome: FIP1L1-PDGFRA fusion gene-positive disease is a distinct clinical entity with myeloproliferative features and a poor response to corticosteroid.  Int J Hematol.  2007  85(1):5-10  PubMed ID: 17261495   DOI: 10.1532/IJH97.06047
3271  Matsunaga T, Yanagiguchi K, Yamada S, Ohara N, Ikeda T, Hayashi Y.  Chitosan monomer promotes tissue regeneration on dental pulp wounds.  J Biomed Mater Res A  2006  76:711-20  PubMed ID: 16315192   DOI: 10.1002/jbm.a.30588
6440  Osaka E, Suzuki T, Osaka S, Yoshida Y, Sugita H, Asami S, Tabata K, Hemmi A, Sugitani M, Nemoto N, Ryu J.  Survivin as a prognostic factor for osteosarcoma patients.  Acta Histochem Cytochem  2006  39(3):95-100  PubMed ID: 17327929   DOI: 10.1267/ahc.06005
2703  Ohara, Naoko, Hayashi, Yoshihiko, Yamada, Shizuka, Kim, Se-Kwon, Matsunaga, Tsunenori, Yanagiguchi, Kajiro, Ikeda, Takeshi  Early gene expression analyzed by cDNA microarray and RT-PCR in osteoblasts cultured with water-soluble and low molecular chitooligosaccharide.  Biomaterials  2004  25:1749-54  PubMed ID: 14738837   DOI: 10.1016/j.biomaterials.2003.08.022
2704  Yamada S, Ohara N, Hayashi Y.  Mineralization of matrix vesicles isolated from a human osteosarcoma cell line in culture with water-soluble chitosan-containing medium.  J Biomed Mater Res A  2003  66:500-6  PubMed ID: 12918032   DOI: 10.1002/jbm.a.10009
6453  Hanaoka E, Ozaki T, Nakamura Y, Moriya H, Nakagawara A, Sakiyama S.  Overexpression of DAN causes a growth suppression in p53-deficient SAOS-2 cells.  Biochem Biophys Res Commun  2000  278(1):20-6  PubMed ID: 11071849   DOI: 10.1006/bbrc.2000.3758


Back Back Return Top Page